Revenue has steadily increased, reaching $254.2 billion for fiscal 2026, up 14% from two years ago, driven by sustained demand. Operating income and EBITDA have shown gradual improvement in margin percentages, yet remain relatively weak compared to revenue scale.

Revenue growth results primarily from higher volumes and product mix shifts in medical and pharmaceutical distribution. While top-line scale is robust, pricing pressures and reimbursement challenges constrain profitability.

Gross margins remain very thin at around 3.8-4.3%, reflecting the low margin nature of distribution business. Operating margins hover slightly above 1% with net income margins under 1%, indicative of high cost structures and competitive pricing.

Earnings quality is moderate; the company demonstrates consistent earnings but faces cost pressures and occasional higher expenses. Reliable cash flow generation supports business continuity but margins are vulnerable to economic and regulatory changes.

Year-over-year revenue growth averaged approximately 12% to 14% over the past two fiscal years, with Q2 2026 up about 6.3% year-over-year, reflecting stable organic volume growth.

Net income increased from $852 million fiscal 2024 to $1.71 billion fiscal 2026, a compound annual growth rate around 36%, supported by operational improvements and cost control efforts.

Growth is primarily fueled by core pharmaceuticals and medical products distribution, expanding healthcare infrastructure demand, and selective pricing improvements. Operational efficiencies and expense management contribute to earnings growth.

Growth is largely organic, supported by steady healthcare demand rather than acquisitive expansion. The sustainability remains dependent on healthcare market dynamics and regulatory environment stability.

Gross margin improved from approximately 3.6% in fiscal 2024 to over 4.3% in Q2 2026 quarters, with operating margin slightly above 1%. Net margins have increased but remain below 1%, reflecting continuing cost and pricing pressures.

Return on equity is limited by thin profitability, likely remaining low single digits. Lack of detailed balance sheet metrics restricts precise ROE/ROA calculation but margins suggest constrained capital returns.

Given the industry's structural low margins and external cost pressures, margin sustainability is a concern. The company has shown progress with operational improvements but economic and regulatory risks pose ongoing challenges.